MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Vendor advances, gross$3,271K Intangible assets, net$102K Deferred offering costs$1,308K Prepaid expenses andother current assets$24K Vendor advances, net$1,057K Cash and cashequivalents$5,575K Less accumulatedamortization$2,214K Total other assets$1,410K Total current assets$6,656K Total assets$8,066K Total liabilities andshareholders equity$8,066K Total shareholdersequity$7,664K Total currentliabilities$402K Accumulated deficit-$12,897K Additional paid-in capital$20,540K Accounts payable andaccrued expenses$402K Common stock, par value0.001, 100,000,000...$21K
Balance Sheet
source: myfinsight.com

Kairos Pharma, LTD. (KAPA)

Kairos Pharma, LTD. (KAPA)